DIAGNOS Closes Non-Brokered Private Placement
DIAGNOS Inc. (TSX Venture: ADK) (OTCQB: DGNOF) has successfully concluded a non-brokered private placement, raising a substantial amount to further its mission of transforming health diagnostics through Artificial Intelligence (AI) technology. This latest funding round amounted to $1,568,600.40, marking a significant step forward for DIAGNOS.
Overview of the Private Placement
The placement involved the issuance of 5,228,668 units, each priced at $0.30. This latest effort adds to the $2,499,999.90 raised earlier, culminating in total proceeds of approximately $4,068,600.30. With the completion of this capital raise, DIAGNOS aims to bolster its product development and operational capabilities.
Details of the Units Issued
Each unit sold during this round consists of one common share and one common share warrant. In total, 5,228,668 warrants have been issued, each allowing the purchase of a share at $0.40 for a period that lasts until April 25, 2026. This provides investors with an opportunity to benefit from the potential growth of the company.
Finders’ Compensation
In recognition of their efforts, DIAGNOS compensated three unrelated firms with cash commissions totaling $18,207. Additionally, an aggregate number of 60,690 finder’s warrants has been allocated, permitting holders to buy shares at a set price, further aligning their interests with the company’s success.
Utilization of Funds
The net proceeds from this private placement are earmarked for various critical areas including the development and commercialization of AI-driven screening services. DIAGNOS is focused on enhancing its regulatory affairs and covering general administrative expenses, underlining its commitment to advancing its innovative health solutions.
Regulatory Compliance and Future Outlook
It is essential to note that all securities acquired in conjunction with the private placement are subject to a statutory hold period, which will conclude on February 26, 2025. This ensures compliance with relevant financial regulations, reinforcing DIAGNOS's commitment to transparency and governance.
About DIAGNOS
DIAGNOS is dedicated to revolutionizing health diagnostics through advanced AI technologies. The corporation's FLAIRE platform is instrumental in the early detection of health issues, providing efficient applications like CARA (Computer Assisted Retina Analysis). This technology not only enhances retinal image clarity but also serves as a powerful tool for real-time screening of a large patient demographic.
Current Innovations and Their Impact
The AI applications developed by DIAGNOS exhibit the potential to significantly streamline the diagnostic process. By utilizing innovative algorithms, DIAGNOS can deliver improved patient outcomes at a reduced cost, thereby playing a pivotal role in the healthcare sector.
Frequently Asked Questions
What is the aim of DIAGNOS's recent private placement?
The private placement aims to raise funds for enhancing product development and commercialization of AI-based health screening services.
How much capital did DIAGNOS raise through this placement?
DIAGNOS raised a total of approximately $4,068,600.30, including previous placements.
What does each unit in the private placement consist of?
Each unit consists of one common share and one common share warrant.
When can the exercise of the warrants begin?
The warrants can be exercised until April 25, 2026, at a price of $0.40 per share.
What is the main technology used by DIAGNOS?
DIAGNOS utilizes its FLAIRE AI platform to conduct early detection of critical health issues, enhancing applications like CARA for efficient imaging.
